These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 26835885)

  • 41. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
    Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
    Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 3'-Deoxy-3'-18F-fluorothymidine PET for the early prediction of response to leucovorin, 5-fluorouracil, and oxaliplatin therapy in patients with metastatic colorectal cancer.
    Hong YS; Kim HO; Kim KP; Lee JL; Kim HJ; Lee SJ; Lee SJ; Oh SJ; Kim JS; Ryu JS; Moon DH; Kim TW
    J Nucl Med; 2013 Aug; 54(8):1209-16. PubMed ID: 23804324
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens.
    Kline CL; Schiccitano A; Zhu J; Beachler C; Sheikh H; Harvey HA; Mackley HB; McKenna K; Staveley-O'Carroll K; Poritz L; Messaris E; Stewart D; Sivik J; El-Deiry WS
    Clin Colorectal Cancer; 2014 Jun; 13(2):119-26. PubMed ID: 24461492
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High-throughput RNAi screening of human kinases identifies predictors of clinical outcome in colorectal cancer patients treated with oxaliplatin.
    Lin M; Zhang Y; Li A; Tang E; Peng J; Tang W; Zhang Y; Lu L; Xiao Y; Wei Q; Yin L; Li H
    Oncotarget; 2015 Jun; 6(18):16774-85. PubMed ID: 25904054
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer.
    Cortejoso L; García MI; García-Alfonso P; González-Haba E; Escolar F; Sanjurjo M; López-Fernández LA
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1463-72. PubMed ID: 23543295
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer.
    Lv H; Li Q; Qiu W; Xiang J; Wei H; Liang H; Sui A; Liang J
    Cancer Invest; 2013 Jan; 31(1):24-8. PubMed ID: 23327191
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of microsatellite instability in the management of colorectal cancers.
    Buecher B; Cacheux W; Rouleau E; Dieumegard B; Mitry E; Lièvre A
    Dig Liver Dis; 2013 Jun; 45(6):441-9. PubMed ID: 23195666
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients.
    Bensmaïne MA; Marty M; de Gramont A; Brienza S; Lévi F; Ducreux M; François E; Gamelin E; Bleiberg H; Cvitkovic E
    Br J Cancer; 2001 Aug; 85(4):509-17. PubMed ID: 11506488
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.
    Monzo M; Moreno I; Navarro A; Ibeas R; Artells R; Gel B; Martinez F; Moreno J; Hernandez R; Navarro-Vigo M
    Oncology; 2007; 72(5-6):364-70. PubMed ID: 18204222
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.
    Comella P; Massidda B; Palmeri S; Putzu C; De Rosa V; Izzo F; Fiore F; Casaretti R; Sandomenico C
    Anticancer Drugs; 2006 Sep; 17(8):985-92. PubMed ID: 16940809
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
    Han SW; Lee HJ; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
    Int J Cancer; 2013 May; 132(9):2209-16. PubMed ID: 23034738
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.
    Boige V; Mendiboure J; Pignon JP; Loriot MA; Castaing M; Barrois M; Malka D; Trégouët DA; Bouché O; Le Corre D; Miran I; Mulot C; Ducreux M; Beaune P; Laurent-Puig P
    J Clin Oncol; 2010 May; 28(15):2556-64. PubMed ID: 20385995
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
    Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR
    Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.
    Graziano F; Ruzzo A; Loupakis F; Canestrari E; Santini D; Catalano V; Bisonni R; Torresi U; Floriani I; Schiavon G; Andreoni F; Maltese P; Rulli E; Humar B; Falcone A; Giustini L; Tonini G; Fontana A; Masi G; Magnani M
    J Clin Oncol; 2008 Mar; 26(9):1427-34. PubMed ID: 18349392
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression quantitative trait loci in ABC transporters are associated with survival in 5-FU treated colorectal cancer patients.
    Vymetalkova V; Rosa F; Susova S; Bendova P; Levy M; Buchler T; Kral J; Bartu L; Vodickova L; Hughes DJ; Soucek P; Naccarati A; Kumar R; Vodicka P; Pardini B
    Mutagenesis; 2020 Jul; 35(3):273-281. PubMed ID: 31922572
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.
    To KK; Leung WW; Ng SS
    Exp Cell Res; 2015 Nov; 338(2):222-31. PubMed ID: 26386386
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comprehensive analysis of colorectal cancer-risk loci and survival outcome: A prognostic role for CDH1 variants.
    Summers MG; Maughan TS; Kaplan R; Law PJ; Houlston RS; Escott-Price V; Cheadle JP
    Eur J Cancer; 2020 Jan; 124():56-63. PubMed ID: 31734605
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene?
    Suh KW; Kim JH; Kim DY; Kim YB; Lee C; Choi S
    Ann Surg Oncol; 2006 Nov; 13(11):1379-85. PubMed ID: 17009149
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.
    Ruff P; Ferry DR; Lakomỳ R; Prausová J; Van Hazel GA; Hoff PM; Cunningham D; Arnold D; Schmoll HJ; Moiseyenko VM; McKendrick JJ; Ten Tije AJ; Vishwanath RL; Bhargava P; Chevalier S; Macarulla T; Van Cutsem E
    Eur J Cancer; 2015 Jan; 51(1):18-26. PubMed ID: 25466509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.